Form 4: VolitionRx Director Awarded Equity Compensation

Ethel Rubin, a Director at VolitionRx Ltd., received 17,424 restricted stock units as compensation, aligning her interests with shareholders.

Summary

• Ethel Rubin, a Director of VolitionRx Ltd. (VNRX), was awarded 17,424 restricted stock units (RSUs).
• The RSUs were granted on August 15, 2025, under the Issuer's 2015 Stock Incentive Plan.
• This award is in lieu of cash compensation that would otherwise have been owed to Ms. Rubin.
• The RSUs will be earned in six approximately equal monthly installments commencing on August 1, 2025.
• Once earned, they are subject to additional time-based vesting in two equal installments of 8,712 units on November 1, 2025, and February 1, 2026.
• Vesting is generally contingent on Ms. Rubin's continued service throughout each applicable earning and vesting date.
• Upon vesting and settlement, Ms. Rubin will receive common stock shares equal to the number of RSUs that have been earned and vested.
• Following this transaction, Ms. Rubin beneficially owns 62,948 shares of common stock.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity compensation award to a director, which is generally positive as it aligns interests. There are no negative financial implications beyond minor future dilution, which is expected with such awards.

Positives

• The award of restricted stock units to a director aligns management's interests with those of shareholders, as their compensation is tied to the company's future stock performance.
• Utilizing equity compensation instead of cash can help conserve the company's cash reserves.

Negatives

• The award of restricted stock units, once vested and settled, will result in a minor dilution of existing shareholder equity.
• The compensation is not immediate cash, which might be a negative for the recipient, but is standard for equity awards.

Risks

• The vesting of the restricted stock units is contingent on the reporting person's continued service, meaning the award could be forfeited if service ceases before vesting dates.

Future Outlook

The award of restricted stock units indicates a future issuance of common stock shares to the director upon successful earning and vesting, contingent on continued service through November 1, 2025, and February 1, 2026.

Industry Context

The practice of compensating directors with equity, such as restricted stock units, is a common and widely accepted practice across various industries. It serves to align the interests of the board members with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is a standard practice, comparable to compensation structures at many publicly traded companies, including those in the biotechnology and diagnostics sectors.
• Companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH) often utilize similar equity-based compensation plans for their non-employee directors to foster long-term commitment and performance alignment.
• The vesting schedule, with earning over several months and subsequent time-based vesting, is typical for RSU awards, ensuring retention and continued service.

Corporate Governance

Related Party Transactions

• The award of restricted stock units to Ethel Rubin, a Director of VolitionRx Ltd., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting and settlement of the RSUs, but also benefits from improved alignment of director interests with long-term company performance.
• Employees: No direct impact on general employees mentioned.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Earning of RSUs in six approximately equal monthly installments commencing August 1, 2025.
• First vesting of 8,712 RSUs on November 1, 2025.
• Second vesting of 8,712 RSUs on February 1, 2026.
• Settlement of vested RSUs into common stock shares.

Key Dates

Keywords

VolitionRx, VNRX, SEC Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation, Director Compensation, Stock Incentive Plan, Corporate Governance